Indication
Ezmekly as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric and adult patients with neurofibromatosis type 1 (NF1) aged 2 years and above.
Loading your page…
Loading your page…
Neurofibromatosis 1;Neurofibroma, Plexiform
Marketing Authorisation Holder: Merck Europe B.V.
EMA Authorisation: 17/07/2025
INN: mirdametinib
AI Drug & Interaction Analysis
Free account required
Ask Osler about Ezmekly: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.